Phase I Multiple-Ascending Dose (Japan) (MAD)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
Dapagliflozin
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Japanese male and female subjects
- Ages 20 to 70 years old
- Established diagnosis of T2DM
- BMI < 32 kg/m2
- Fasting glucose ≤ 240 mg/dL, while on antidiabetic diet alone
- HbA1C 6.0 - 10.0%
Exclusion Criteria:
- Symptomatic T2DM defined as polyuria and/or polydipsia within 2 months of enrollment
- History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome
- History of incontinence or bladder dysfunction including nocturia
Sites / Locations
- Local Institution
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
Arm 1
Arm 2
Arm 3
Arm 4
Arm Description
2.5 mg
10 mg
20 mg
Outcomes
Primary Outcome Measures
AEs, vital signs & physical exam
ECGs
Clinical labs
Urine safety markers
Secondary Outcome Measures
24 hr PK blood & urine samples
Serum glucose, serum insulin, serum c-peptide
Serum fructosamine
OGTT
24h urine
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00538174
Brief Title
Phase I Multiple-Ascending Dose (Japan)
Acronym
MAD
Official Title
A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following once daily oral doses of 2.5, 10, and 20 mg of dapagliflozin in diabetic Japanese subjects administered for 14 days
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm 1
Arm Type
Experimental
Arm Description
2.5 mg
Arm Title
Arm 2
Arm Type
Experimental
Arm Description
10 mg
Arm Title
Arm 3
Arm Type
Experimental
Arm Description
20 mg
Arm Title
Arm 4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Intervention Description
Tablets, Oral, once daily up, to 14 days
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Tablets, Oral, 0 mg, once daily, up to 14 days
Primary Outcome Measure Information:
Title
AEs, vital signs & physical exam
Time Frame
scr, Days -3, -1, 1, 2, 7, 12, 13, 14, 15, 21
Title
ECGs
Time Frame
scr, Days -1, 1, 2, 7, 12, 13, 14, 15, 21
Title
Clinical labs
Time Frame
scr, Days -1, 2, 7, 12, 14, 15, 21
Title
Urine safety markers
Time Frame
Days -1, 1, 14
Secondary Outcome Measure Information:
Title
24 hr PK blood & urine samples
Time Frame
Days 1 & 14
Title
Serum glucose, serum insulin, serum c-peptide
Time Frame
Days -1, 1, 14
Title
Serum fructosamine
Time Frame
Days -1, 14, 4 h
Title
OGTT
Time Frame
Days -2, 13 (after 10 h fast)
Title
24h urine
Time Frame
Days -1, 1 & 14 for glucose, creatinine & calcium
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Japanese male and female subjects
Ages 20 to 70 years old
Established diagnosis of T2DM
BMI < 32 kg/m2
Fasting glucose ≤ 240 mg/dL, while on antidiabetic diet alone
HbA1C 6.0 - 10.0%
Exclusion Criteria:
Symptomatic T2DM defined as polyuria and/or polydipsia within 2 months of enrollment
History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome
History of incontinence or bladder dysfunction including nocturia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers K.K.
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution
City
Suita
State/Province
Osaka
ZIP/Postal Code
5650853
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
21226818
Citation
Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x.
Results Reference
result
Learn more about this trial
Phase I Multiple-Ascending Dose (Japan)
We'll reach out to this number within 24 hrs